Linking Genome-Wide Association Studies to Pharmacological Treatments for Psychiatric Disorders.

ABSTRACT:

Importance

Large-scale genome-wide association studies (GWAS) should ideally inform the development of pharmacological treatments, but whether GWAS-identified mechanisms of disease liability correspond to the pathophysiological processes targeted by current pharmacological treatments is unclear.

Objective

To investigate whether functional information from a range of open bioinformatics datasets can elucidate the relationship between GWAS-identified genetic variation and the genes targeted by current treatments for psychiatric disorders.

Design, setting, and participants

Associations between GWAS-identified genetic variation and pharmacological treatment targets were investigated across 4 psychiatric disorders-attention-deficit/hyperactivity disorder, bipolar disorder,

SUBMITTER: Arnatkeviciute A 

PROVIDER: S-EPMC11800018 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature